March 2015
MondayMorning;3/9/2015, Vol. 23 Issue 10, p1
The article offers information related to pharmaceutical industry in the U.S. as of March 2015. Topics discussed include the acquisition of Pharmacyclics Inc. by pharmaceutical research firm AbbVie for worth US$21 billion, the plan of Cardinal Health to acquire Cordis cardiology medical-device business from Johnson & Johnson (J&J) for worth US$2 billion, and the approval of the Zarxio, a biosimilar drug from Sandoz Inc., by the Food and Drug Administration (FDA).


Related Articles

  • Medical Stocks Highlight The Day's New Highs. JUAN CARLOS ARANCIBIA // Investors Business Daily;3/6/2015, pB01 

    The article focuses on the medical sector as the capable leader in the securities market in the U.S. due to their high stock on March 5, 2015. Topics include the plan of drugmaker AbbVie to acquire Pharmacyclics for $21 billion, the high stock of Pernix Therapeutics after surpassing its profit...

  • J&J selling medical-device unit for nearly $2B. Strauss, Eric // njbiz;3/9/2015, Vol. 28 Issue 10, p3 

    The article reports on the plan of health care company Johnson & Johnson as of March 2015 to sell its Cordis medical device unit to Cardinal Health as part of its ongoing disciplined portfolio management approach to focus on their most promising opportunities.

  • Pharmacyclics up on FDA OK. Investor's Business Daily // Investors Business Daily;2/13/2014, pA02 

    Imbruvica, a drug developed by

  • Investors Pan AbbVie's Offer. Investor's Business Daily // Investors Business Daily;3/6/2015, pA01 

    4 The drug giant's $21 bil offer for

  • JOHNSON & JOHNSON. Investor's Business Daily // Investors Business Daily;3/5/2015, pA02 

    The article reports on the buyout deal being signed by the U.S. multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson and Johnson for Pharmacyclics Inc.

  • Competitive Landscape.  // U.S. Pharma & Healthcare Report;Q2 2012, Issue 2, p69 

    The article discusses the research-based, competitive U.S. pharmaceutical industry. Pfizer, it says, is the largest pharmaceutical company with operations in the U.S. in terms of value followed by Merck & Co., Abbott and Johnson and Johnson and the industry employing 686,000 Americans as of 2006...

  • AbbVie-Pharmacyclics Questioned. AMY REEVES // Investors Business Daily;3/6/2015, pA04 

    The article reports on the skepticism met by the deal of pharmaceutical company AbbVie to acquire biotechnology company Pharmacyclics (PCYC) for $21 billion from the company's investors. Analyst Geoffrey Porges of a global asset management firm Bernstein, argues that what does not make sense to...

  • Pharmacyclics hits new high. Investor's Business Daily // Investors Business Daily;2/26/2015, pA02 

    The article reports on the growth of drug sales of Pharmacyclics, a biotechnology company, and the marketing of the Imbruvica, a drug for blood cancer treatment, with healthcare products manufacturer Johnson & Johnson (J&J).

  • CORPORATE.  // MondayMorning;6/1/2015, Vol. 23 Issue 21, p2 

    The article offers news briefs in the U.S. pharmaceutical industry as of June 2015. Topics include the merger of drugmakers Endo International PLC and Par Pharmaceutical Holdings Inc., the partnership of Achillion Pharmaceuticals Inc. and Johnson & Johnson in the development and marketing of a...

  • TOP STORIES.  // MondayMorning;7/21/2014, Vol. 22 Issue 27, p1 

    The article offers news briefs related to the healthcare industry. Topics include the $55-billion deal signed by AbbVie Inc. to acquire Shire Plc in Dublin, England, the revenue increase of Johnson & Johnson (J&J) in 2014 due to its hepatitis C pill Olysio, and the report by the U.S....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics